Latest Lactams Stories
Data Evaluating the Effect of Repatha(TM)(Evolocumab) on LDL-C and Cardiovascular Events to be Featured in Late-Breaking Session THOUSAND OAKS, Calif., March 2, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
Pharmaceutical manufacturer, Johnson & Johnson, loses $2.5 million verdict for marketing of Risperdal, a potent antipsychotic that caused female breast growth in a young boy the case revealed.
Recent research reveals that 40 percent of men who experience erectile dysfunction are aged 40 or under.
The Risperdal trial currently underway in the Pennsylvania mass tort, where Bernstein Liebhard LLP is actively filing claims, is the first to involve gynecomastia, and could provide insight into
Science has potentially found a biological impotence solution that can be extracted from the venom of the Brazilian wandering spider and delivered with the help of genetic modification.
The Firm is representing numerous clients in Risperdal lawsuits that allege gynecomastia in the Philadelphia Court of Common Pleas. New York, NY (PRWEB) February
The Firm is representing numerous plaintiffs who have also filed Risperdal lawsuits alleging the atypical antipsychotic medication caused male breast growth. New
Trial in Philadelphia involves allegations that Janssen Pharmaceuticals and parent company, Johnson & Johnson, failed to warn about the risks of male breast growth, a condition known as gynecomastia,
The Firm is representing numerous gynecomastia plaintiffs in Risperdal lawsuits that are now pending in the same Pennsylvania mass tort litigation. New York,
PINEHURST, N.C., Feb.